Changes in clinical guidelines for the treatment of colorectal cancer in 2024

Author:

Gordeev S. S.1ORCID,Fedyanin M. Yu.2ORCID,Chernykh M. V.1ORCID,Rubakov Ye. G.3ORCID,Karachun A. M.4ORCID,Nevolskikh A. A.5ORCID,Tryakin A. A.1ORCID,Mamedli Z. Z.1ORCID

Affiliation:

1. N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

2. N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; Moscow Multidisciplinary Clinical Center “Kommunarka”, Moscow Healthcare Department

3. A.N. Ryzhikh National Medical Research Center of Coloproctology, Ministry of Health of Russia

4. N.N. Petrov Research Institute of Oncology, Ministry of Health of Russia

5. A. F. Tsyb Medical Radiological Research Center – a branch of the National Medical Research Radiology Center, Ministry of Health of Russia

Abstract

Aim. The ensuring that changes to clinical guidelines can be discussed more widely before they are formally introduced into clinical practice.Materials and methods. A brief review of the literature and rationale for each proposed major change in the treatment section is presented. The refusal to carry out preoperative radiation therapy for cancer of the upper ampullary rectum, the narrowing of indications for preoperative radiation therapy for cancer of the mid-ampullary rectum, as well as the expansion of indications for total non-adjuvant chemotherapy for rectal cancer with damage to the circular resection margin are discussed. Changes to the drug treatment section are discussed.Results. This article presents planned changes to clinical guidelines for the treatment of non-metastatic colorectal cancer in 2024. The most significant alterations concerned neoadjuvant treatment of rectal cancer and adjuvant treatment of colon cancer. A new algorithm was proposed for choosing rectal cancer neoadjuvant therapy, considering individual treatment decisions.Conclusion. A consensus was achieved concerning the necessity to expand indications for neoadjuvant rectal cancer chemotherapy, but only in patients with good functional status. The most benefit can be achieved in patients, for whom complete clinical response is the aim of the treatment and in patients with positive circumferential resection margin.

Publisher

Publishing House ABV Press

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3